摩根士丹利上调阿里健康目标价至5港元

Group 1 - Morgan Stanley adjusted the target price for Alibaba Health to HKD 5 after the company announced its half-year performance, maintaining an "Overweight" rating [1] - The bank forecasts revenue growth rates for Alibaba Health at 11%, 10%, and 10% for the fiscal years 2025 to 2027 [1] - Expected IFRS net profit margins are projected to reach 5.3%, 6.7%, and 8% over the same period, with an average annual compound growth rate of 35% for IFRS net profit over the next three years [1]